Navigation Links
Antiviral enzyme contributes to several forms of cancer, University of Minnesota researchers say
Date:7/14/2013

Researchers at the University of Minnesota have discovered that a human antiviral enzyme causes DNA mutations that lead to several forms of cancer.

The discovery, reported in the July 14 issue of Nature Genetics, follows the team's earlier finding that the enzyme, called APOBEC3B, is responsible for more than half of breast cancer cases. The previous study was published in Nature in February.

APOBEC3B is part of a family of antiviral proteins that Harris has studied for more than a decade. His effort to understand how these proteins work has led to these surprising discoveries that APOBEC3B is a broadly important cancer mutagen.

"We are very excited about this discovery because it indicates that a single enzyme is one of the largest known contributors to cancer mutation, possibly even eclipsing sources such as UV rays from the sun and chemicals from smoking," says Reuben Harris, a professor of biochemistry, molecular biology and biophysics based in the College of Biological Sciences. Harris, who led the study, is also a member of the Masonic Cancer Center, University of Minnesota.

For the current study, Harris, along with colleagues Michael Burns and Alpay Temiz, analyzed tumor samples from 19 different types of cancer for the presence of APOBEC3B and 10 related proteins. Results showed that APOBEC3B alone was significantly elevated in six types (bladder, cervix, two forms of lung cancer, head & neck, and breast). Levels of the enzyme, which is present in low levels in most healthy tissues, were elevated in several other types of cancer as well.

A second key finding was that the mutational signature of APOBEC3B is a close match to the actual mutation pattern in these cancers. "Much like we each have unique written signatures, these enzymes each leave a unique mark," Harris says.

Findings from both studies are counterintuitive because the enzyme, which is produced by the immune system, is supposed to protect cells from HIV and other viruses, not harm our own genomic DNA.

While it's well known that sunlight and chemical carcinogens can mutate DNA, and that mutations are essential for cancer to develop, Harris is the first to discover that this human enzyme is a major cause mutation in cancer. He believes that APOBEC3B is a biological "double-edged sword" that protects some cells from viruses such as HIV and produces mutations that give rise to cancer in others.

Harris hopes to find a way to block APOBEC3B from mutating DNA, just as sunscreen blocks mutations that lead to melanoma. Many cancer mutations have been identified, but discovering a common source of mutation such as APOBEC3B is expected to help researchers to move "upstream" and look for a way to stop carcinogenesis closer to its source, he says, "like damming a river before it wreaks havoc on downstream areas." It's also possible that a simple test for APOBEC3B could be used to detect cancer earlier.

Harris is a professor in the Department of Biochemistry, Molecular Biology and Biophysics, which is a joint department of the College of Biological Sciences and the Medical School. He is also a member of the Masonic Cancer Center, University of Minnesota, which is part of the National Cancer Institute's network of Comprehensive Cancer Centers. Harris and colleagues are grateful for support from the National Institutes of Health, the Department of Defense Breast Cancer Research Program, the Jimmy V Foundation, and the Minnesota Ovarian Cancer Alliance.


'/>"/>

Contact: Peggy Rinard
rinar001@umn.edu
612-624-0774
University of Minnesota
Source:Eurekalert

Related biology news :

1. Scientists identify promising antiviral compounds
2. Toward broad-spectrum antiviral drugs for common cold and other infections
3. Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies
4. Antiviral lipid earns patent
5. Novel enzyme from tiny gribble could prove a boon for biofuels research
6. Combining strategies speeds the work of enzymes
7. Protein improves efficacy of tumor-killing enzyme
8. Enzymes allow DNA to swap information with exotic molecules
9. DNA catalysts do the work of protein enzymes
10. Researchers divide enzyme to conquer genetic puzzle
11. Organizing enzymes to create electricity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... N.J. , Jan. 11, 2017  Michael Johnson, co-founder of ... Venture Capital Group, Inc., has been named to the elite "Forbes ... 27,  was one of 600 people in 20 fields nationwide to ... percent of the 15,000 applicants were selected. ... He is currently a PhD candidate at ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
Breaking Biology Technology: